Fourth-generation retinoid with selective action on RAR-gamma receptors. Galderma markets it as Aklief for facial and truncal acne.
Topical application
AProven efficacy. Two or more independent RCTs with instrumental endpoints.
FDA approved trifarotene in 2019 as the first retinoid with proven efficacy for truncal acne. The selectivity reduces irritation compared with tretinoin.
Irritation potential
MediumAllergen risk
LowPregnancy
AvoidUse with caution
Trifarotene is not recommended during pregnancy. Consider an alternative from the same category.
Use with caution in: sensitive.
Trifarotene has moderate irritation potential. Sensitive skin may show a transient reaction that usually settles with adaptation.
Fourth-generation retinoid with selective action on RAR-gamma receptors.
The INCI name is Trifarotene.
Published: · updated: